Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21451639 | 1.00 | CYP2D6 (0.40) | CYP2D6HRH3KDM4EMEN1ALDH1A1 | |
| SCHEMBL21451660 | 1.00 | CYP2D6 (0.40) | CYP2D6HRH3KDM4EMEN1ALDH1A1 | |
| SCHEMBL19756479 | 0.88 | CYP2D6 (0.34) | CYP2D6HRH3 | |
| SCHEMBL20909285 | 0.88 | HRH3 (0.38) | CYP2D6HRH3 | |
| SCHEMBL9963286 | 0.88 | HRH3 (0.38) | CYP2D6HRH3 | |
| SCHEMBL20112178 | 0.88 | HRH3 (0.38) | CYP2D6HRH3 | |
| SCHEMBL21776106 | 0.84 | — | — | |
| SCHEMBL22048913 | 0.84 | — | — | |
| SCHEMBL21451623 | 0.83 | CYP2D6 (0.42) | CYP2D6HRH3KDM4EMEN1ALDH1A1 | |
| SCHEMBL21451640 | 0.83 | CYP2D6 (0.42) | CYP2D6HRH3KDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11529347-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| WO-2020150372-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | CURZA GLOBAL, LLC (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200172546-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS, INC. | 2020-06-04 | — | — | US | disclosed |
| US-20200062760-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-20190307745-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20170369498-A1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062760-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPRJ, PTPRC | CYP2D6 4575/4885HRH3 3727/4885KDM4E 876/4885 |
| US-20190307745-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPN21, PTPN5, PTPN1 | CYP2D6 4253/4885HRH3 2546/4885KDM4E 2017/4885 |
| US-20200172546-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | PTPRJ, PTPN2, PTPN5 | CYP2D6 3453/4885HRH3 4514/4885KDM4E 1215/4885 |
| US-11529347-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPN21, PTPN22, PTPN5 | CYP2D6 4022/4885HRH3 2558/4885KDM4E 2010/4885 |
| US-20170369498-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | CYP2D6 84/4885HRH3 4651/4885KDM4E 2371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.